CR-CP Life Science Fund

Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.

NuProbe is a genomics and molecular diagnostics company that develops a platform of reagents and genetic toehold probes for noninvasive nucleic acid profiling. Their Sample‑In Answer‑Out solution integrates cell‑free DNA extraction, qPCR, sequencing and bioinformatics to detect mutations, CNVs, gene fusions and low‑frequency variants with high sensitivity. Founded in 2016, the company operates from Cambridge, Massachusetts and Shanghai, China, and focuses on early detection of cancer and infectious diseases for clinical and research use.

MiRXES Pte. Ltd., founded in 2014 and based in Singapore, specializes in life science research tools and molecular diagnostic tests for both research and clinical applications. The company has developed a leading microRNA (miRNA) detection assay platform designed to identify cancer at asymptomatic stages. Its product offerings include RT-qPCR assays, assay panels, spike-in RNA kits, and solutions for biomarker discovery. By focusing on early cancer detection, MiRXES provides healthcare professionals with essential diagnostic tools to improve clinical outcomes through timely intervention.

MiRXES Pte. Ltd., founded in 2014 and based in Singapore, specializes in life science research tools and molecular diagnostic tests for both research and clinical applications. The company has developed a leading microRNA (miRNA) detection assay platform designed to identify cancer at asymptomatic stages. Its product offerings include RT-qPCR assays, assay panels, spike-in RNA kits, and solutions for biomarker discovery. By focusing on early cancer detection, MiRXES provides healthcare professionals with essential diagnostic tools to improve clinical outcomes through timely intervention.

EyeYon Medical Ltd., based in Jerusalem, Israel, develops innovative medical devices for treating corneal edema. Its flagship product is Hyper-CL, a hyperosmotic contact lens that extracts fluids from the cornea by osmosis, improving vision and relieving pain.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

BELKIN Vision is a company focused on developing innovative laser devices to aid healthcare professionals in the treatment of glaucoma. Its products are characterized by being non-invasive, non-contact, instantaneous, painless, and automated, providing effective laser therapy options. The company's mission is to enhance accessibility to first-line drop-less glaucoma care, enabling any ophthalmologist to effectively treat patients. By streamlining the treatment process, BELKIN Vision aims to improve patient outcomes and overall quality of care within the medical community.

New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Genor BioPharma Co., Ltd. is a Shanghai-based biopharmaceutical company focused on discovering, developing, and commercializing therapeutic biologics, including monoclonal antibodies and Fc-fusion proteins, with a portfolio spanning oncology, autoimmune, and metabolic diseases. The company pursues both biosimilars and novel molecules and maintains a pipeline with multiple candidates in clinical development, supported by collaborations with industry partners such as Ascentage Pharma to advance its programs. Founded in 2007, Genor aims to deliver affordable therapeutics to patients and positions itself as a science-driven organization advancing high-need therapeutic areas.

Transcenta Holding is a clinical-stage biopharmaceutical company that offers fully integrated capabilities in antibody discovery, research and development, manufacturing, and business development. The company concentrates on developing innovative antibody-based therapeutics for oncology and selected non-oncology indications, including bone and kidney disorders, with a pipeline that includes Osemitamab (TST001), TST002, TST003, TST006, MSB2311, MSB0254, TST808, and other candidates. Headquartered with multiple sites in China—Suzhou, Shanghai, Hangzhou, and Beijing—and with research and development and operations in the United States at Waltham and Princeton, Transcenta operates as a global biotherapeutics business. Founded in 2019, the company aims to advance therapeutic antibodies through discovery, development, and manufacturing to address unmet patient needs. Its business scope encompasses clinical research and trial services alongside its development programs, positioning it to accelerate pipeline progress and collaborate on global opportunities.

CF PharmTech, Inc. is an independent specialty pharmaceutical company founded in 2007 and headquartered in Suzhou, China. The company specializes in the development and manufacturing of inhalation products, including metered dose inhalers, dry powder inhalers, nasal sprays, and nebulizers. CF PharmTech focuses on creating high-quality and affordable medications for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. In addition to its product development efforts, the company provides contract manufacturing organization (CMO) services, enhancing its capabilities in the global market. With a commitment to effective patient care, CF PharmTech aims to improve management of respiratory conditions through its innovative offerings.

Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.